678 related articles for article (PubMed ID: 28491060)
1. Shaping of Natural Killer Cell Antitumor Activity by
Granzin M; Wagner J; Köhl U; Cerwenka A; Huppert V; Ullrich E
Front Immunol; 2017; 8():458. PubMed ID: 28491060
[TBL] [Abstract][Full Text] [Related]
2. A Two-Phase Expansion Protocol Combining Interleukin (IL)-15 and IL-21 Improves Natural Killer Cell Proliferation and Cytotoxicity against Rhabdomyosarcoma.
Wagner J; Pfannenstiel V; Waldmann A; Bergs JWJ; Brill B; Huenecke S; Klingebiel T; Rödel F; Buchholz CJ; Wels WS; Bader P; Ullrich E
Front Immunol; 2017; 8():676. PubMed ID: 28659917
[TBL] [Abstract][Full Text] [Related]
3. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
[TBL] [Abstract][Full Text] [Related]
4. An Uncoupling of Canonical Phenotypic Markers and Functional Potency of
Lieberman NAP; DeGolier K; Haberthur K; Chinn H; Moyes KW; Bouchlaka MN; Walker KL; Capitini CM; Crane CA
Front Immunol; 2018; 9():150. PubMed ID: 29456538
[TBL] [Abstract][Full Text] [Related]
5. Building a Better Defense: Expanding and Improving Natural Killer Cells for Adoptive Cell Therapy.
Maia A; Tarannum M; Lérias JR; Piccinelli S; Borrego LM; Maeurer M; Romee R; Castillo-Martin M
Cells; 2024 Mar; 13(5):. PubMed ID: 38474415
[TBL] [Abstract][Full Text] [Related]
6. The human ortholog of granulocyte macrophage colony-stimulating factor and interleukin-2 fusion protein induces potent ex vivo natural killer cell activation and maturation.
Penafuerte C; Bautista-Lopez N; Boulassel MR; Routy JP; Galipeau J
Cancer Res; 2009 Dec; 69(23):9020-8. PubMed ID: 19920194
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic applications: natural killer cells in the clinic.
Miller JS
Hematology Am Soc Hematol Educ Program; 2013; 2013():247-53. PubMed ID: 24319187
[TBL] [Abstract][Full Text] [Related]
8. Highly efficient IL-21 and feeder cell-driven
Granzin M; Stojanovic A; Miller M; Childs R; Huppert V; Cerwenka A
Oncoimmunology; 2016; 5(9):e1219007. PubMed ID: 27757317
[TBL] [Abstract][Full Text] [Related]
9. Natural killer cell receptors: alterations and therapeutic targeting in malignancies.
Konjević G; Vuletić A; Mirjačić Martinović K
Immunol Res; 2016 Feb; 64(1):25-35. PubMed ID: 26374324
[TBL] [Abstract][Full Text] [Related]
10. Ex vivo expansion of highly cytotoxic human NK cells by cocultivation with irradiated tumor cells for adoptive immunotherapy.
Lim SA; Kim TJ; Lee JE; Sonn CH; Kim K; Kim J; Choi JG; Choi IK; Yun CO; Kim JH; Yee C; Kumar V; Lee KM
Cancer Res; 2013 Apr; 73(8):2598-607. PubMed ID: 23580577
[TBL] [Abstract][Full Text] [Related]
11. Carfilzomib combined with ex vivo-expanded patient autologous natural killer cells for myeloma immunotherapy.
Chang SK; Hou J; Chen GG; Yu DD; Wu HQ; Xie YS; Hu LN; Gao L; Xiao WQ; Kong YY; Tao Y; Shi JM
Neoplasma; 2018 Sep; 65(5):720-729. PubMed ID: 29940772
[TBL] [Abstract][Full Text] [Related]
12. Cytokines impact natural killer cell phenotype and functionality against glioblastoma
Sivonen M; Sirviö KA; Wojciechowski S; Kailaanmäki A; Kaipainen S; Bailey A; Villalba M; Kekarainen T
Front Immunol; 2023; 14():1227064. PubMed ID: 37841273
[TBL] [Abstract][Full Text] [Related]
13. Genetically re-engineered K562 cells significantly expand and functionally activate cord blood natural killer cells: Potential for adoptive cellular immunotherapy.
Ayello J; Hochberg J; Flower A; Chu Y; Baxi LV; Quish W; van de Ven C; Cairo MS
Exp Hematol; 2017 Feb; 46():38-47. PubMed ID: 27765614
[TBL] [Abstract][Full Text] [Related]
14. Insufficient natural killer cell responses against retroviruses: how to improve NK cell killing of retrovirus-infected cells.
Littwitz-Salomon E; Dittmer U; Sutter K
Retrovirology; 2016 Nov; 13(1):77. PubMed ID: 27821119
[TBL] [Abstract][Full Text] [Related]
15. A New Ex Vivo Method for Effective Expansion and Activation of Human Natural Killer Cells for Anti-Tumor Immunotherapy.
Yang H; Tang R; Li J; Liu Y; Ye L; Shao D; Jin M; Huang Q; Shi J
Cell Biochem Biophys; 2015 Dec; 73(3):723-9. PubMed ID: 27259316
[TBL] [Abstract][Full Text] [Related]
16. Selection and expansion of natural killer cells for NK cell-based immunotherapy.
Becker PS; Suck G; Nowakowska P; Ullrich E; Seifried E; Bader P; Tonn T; Seidl C
Cancer Immunol Immunother; 2016 Apr; 65(4):477-84. PubMed ID: 26810567
[TBL] [Abstract][Full Text] [Related]
17. Multiple effects of IL-21 on human NK cells in ex vivo expansion.
Li Q; Ye LJ; Ren HL; Huyan T; Li J; Shi JL; Huang QS
Immunobiology; 2015 Jul; 220(7):876-88. PubMed ID: 25758713
[TBL] [Abstract][Full Text] [Related]
18. Synergistic cytotoxicity of ex vivo expanded natural killer cells in combination with monoclonal antibody drugs against cancer cells.
Deng X; Terunuma H; Nieda M; Xiao W; Nicol A
Int Immunopharmacol; 2012 Dec; 14(4):593-605. PubMed ID: 23063974
[TBL] [Abstract][Full Text] [Related]
19. In vitro analysis of the proliferative capacity and cytotoxic effects of ex vivo induced natural killer cells, cytokine-induced killer cells, and gamma-delta T cells.
Niu C; Jin H; Li M; Xu J; Xu D; Hu J; He H; Li W; Cui J
BMC Immunol; 2015 Oct; 16():61. PubMed ID: 26458364
[TBL] [Abstract][Full Text] [Related]
20. Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies.
Matosevic S
J Immunol Res; 2018; 2018():4054815. PubMed ID: 30306093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
